Shigatoxin-producing F18 type E. coli bacteriophage esc-COP-1 and use thereof for inhibiting proliferation of shigatoxin-producing F18 type E. coli
US-10265355-B2 · Apr 23, 2019 · US
Escherichia coli bacteriophage Esc-COP-9 and use for inhibiting proliferation of pathogenic Escherichia coli thereof
US11213050B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11213050-B2 |
| Application number | US-201716464872-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 29, 2017 |
| Priority date | Nov 30, 2016 |
| Publication date | Jan 4, 2022 |
| Grant date | Jan 4, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) isolated from nature, which has the ability to specifically kill Escherichia coli and which includes a genome expressed by SEQ. ID. NO: 1, and to a method of preventing and treating a pathogenic Escherichia coli infection using a composition including the same as an active ingredient.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating a pathogenic Escherichia coli infection, the method comprising: administering to an animal other than a human a composition including the Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) that can kill pathogenic Escherichia coli specifically, which has the genome represented by SEQ. ID. NO: 1, as an active ingredient. 2. The method for treating the pathogenic Escherichia coli infection of claim 1 , wherein said composition is administered to the animal other than the human for use of a feed additive, a drinking-water additive, or a disinfectant.
Assignees
Inventors
Classifications
- A23K10/16Primary
Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions (A23K10/12 takes precedence) · CPC title
Viruses, e.g. bacteriophages · CPC title
Viruses; Subviral particles; Bacteriophages · CPC title
Uses of virus other than therapeutic or vaccine, e.g. disinfectant · CPC title
- C12N7/00Primary
Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11213050B2 cover?
- The present invention relates to a Siphoviridae bacteriophage Esc-COP-9 (Accession number: KCTC 13131BP) isolated from nature, which has the ability to specifically kill Escherichia coli and which includes a genome expressed by SEQ. ID. NO: 1, and to a method of preventing and treating a pathogenic Escherichia coli infection using a composition including the same as an active ingredient.
- Who is the assignee on this patent?
- Intron Biotechnology Inc
- What technology area does this patent fall under?
- Primary CPC classification A23K10/16. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).